ABSTRACTS
Origin of Human Cancer E. FARBER, University of Toronto, Toronto, Canada It is proposed to discuss three aspects of the origin of human cancers, especially as they relate to "animal tumor data": etiology, pathogenesis. and-the neoplastic phenotypes.
With respect to etiology, there is a close correspondence in principle between cancer in humans and in experimental animals. DNA and some RNA viruses, radiations, and chemicals are the major classes of agents. These are influenced in a major way by modifiers: genetic background, hormones, diet, and immunologic status.
With respect to pathogenesis, the major and dominant phenomenon is the long period of time. In humans, a short time period between initiation of exposure and appearance of cancer is 10 years.
Usually, 20 years or longer seems to be the norm. This is also seen in the experimental animal where one-third to one-half or more of the life span may be required for cancer development. What does this mean mechanistically? Clearly, we are dealing with at least a few steps each of low probability. This is also seen in the focal nature of many steps in the process. Another key issue in pathogenesis is cell or tissue of origin. Newer data in the rat liver carcinogenesis strongly suggests that cancer does not arise from fetal or embryonic cells, but rather from a totally new physiologic state of differentiation of liver cells, as represented by the hepatocyte nodule. The possible role of genes ("oncogenes") in the pathogenetic mechanisms will be discussed. Itmust be pointed out that so far only a maximum of 15% of human cancers have shown the activity of oncogenes. Whether this is truly a reflection of the phenomenon or merely a reflection of the deficiencies in technology remains to be clarified.
The cancer phenotypes in many instances in humans and in experimental animals are similar. There is no convincing evidence that malignant neoplasia is not basically a similar phenomenon in both groups. The possible importance of heterogeneity and diversity versus commonality in the neoplastic process will be briefly discussed.
Prognostic Role of Cell Morphology of Human Tumors H. E. NIEBURGS, The Mount Sinai iMedical Center, New York, NY Cell structures permit identification of morphologic features that reflect a variety of benign, preneoplastic, and malignant neoplastic conditions. Pathologic changes in the architecture of a tissue depend upon prior cellular abnormalities, the duration and rate of cell replication, differentiation, and cell survival time. In developing tumors, therefore, the cellular changes may precede the pathologic alteration of the tissue pattern, whereas in malignant tumors a close relationship exists between cell structure and the histologic architecture. In healthy tissues, cells move out of the mitotic cycle in the Go phase to undergo differentiation and eventual cell death. In oncogenesis, the duration of mitosis may be prolonged with cells exiting the cycle in other phases either permanently with prolonged survival time, or more frequently, temporarily to reenter the cycle after varying periods of time. Because mitotic phases are reflected in the nuclear morphology of cells. the prevailing abnormality of cell kinetics, the potentially malignant features. and various malignant changes may be identified for diagnostic and prognostic assessment.
In conditions that may undergo malignant transformation, such as dysplasias, polyps, ulcer-TOXICOLOGIC PATHOLOGY ative colitis, and benign tumors, the malignant potential may be identified by the altered cell morphology within the benign-appearing tissue. For example, the malignant potential of uterine cervix dysplasias is reflected by hyperchromatic cells in the early Gz phase.
In malignant tumors the assessment of prognosis may be made by nuclear abnormalities and abnormal cell kinetics. Cells prolonged in the G1 phase exert a different influence on the course of the disease than those in the G2 phase. GI periods are generally longer in slowly growing cell populations than in rapidly growing cells. Therefore, patients with tumors consisting of cells in the G1 phase, when not treated with antineoplastic drugs, have a better prognosis than those with tumor cells in the G, phase that reflect a large growth fraction with unrestrained cell replications.
Assessment of response to chemotherapy may be made on the basis of tumor cell kinetics. Patients with tumors consisting of cells in the G1 phase have a significantly shorter survival than patients with tumor cells in the G, phase. The decreased responsiveness of tumors composed of cells with a prolonged G1 phase occurs because in such cases antineoplastic drugs, directed to affect either DNA synthesis or cells in DNA syntheses, may affect only a small fraction of cycling cells. The greater responsiveness to chemotherapy of tumors with GZ cells apparently results from the larger number of cells that pass through the S phase and are approaching mitosis to be destroyed by cell cycle-specific drugs that affect DNA synthesis and the mitotic phase.
In terminal cancer patients on chemotherapy, particular nuclear alterations in lymphocytes and epithelial cells were identical with lymphocyte changes in patients with acquired immune deficiency syndrome and were therefore interpreted as manifestations of 'severe immunodeficiency. The prodromal role of these changes in homosexuals is presently under investigation.
Cell kinetic-related morphologic changes were also observed in animals during spontaneous and experimen tal carcinogenesis. This approach permitted prognostic assessment of experimentally induced early neoplastic alterations.
Origin of Animal Cancer S. D. VESSELINOvITCH,The University of Chicago, Chicago, IL The origin of animal tumors will'be discussed in relation to the etiology, underlying mechanism, and morphology. Etiologically the animal tumors can be related .to the viruses (murine leukemia, chicken leukosis, mouse mammary tumors), the genetic background resulting from experimental in-breeding selection leading to the development of a great variety of inbred strains, showing characteristic neoplastic profiles. the variety of chemical agents which have been used either as experimental tools to study mechanisms of carcinogencsis at specific tissue sites or as test compounds to screen for their potential carcinogenicity. In the latter case, in general, no attempt has been made to unearth mechanistic relationships between exposure to a given test compound and the development of the neoplasia. In addition to chemicals, irradiation completes the categories which relate to cancer etiology. The current interpretation of the mechanism regarding the critical carcinogenic event resides within the area of somatic mutation. The latter phenomena relates either to deletion, rearrangement, or translocation of genetic material. The change in the critical nucleotide sequence can be identified through the usage of the appropriate methodology, or even at the chromosomal level, which, in turn, could be correlated with the specific tumor development. The interference with the repressor genes also may be considered as one of the mechanisms. The target tissue and the morphologic entity giving rise to neoplasia varies frequently from one species to another. The tumors of the Harderian gland in mice and ihe Zymbal gland in rats may be considered as 'species-specific neoplasia. The development of interstitial testicular tumors in rats represents a spontaneously developing process which is species-characteristic and its incidence can be modulated by the change in the hormonal environment and the genetic background of the host. This type of neoplasia contrasts with the germinal cell tumors developing in man. Similarly, the alveolar pulmonary tumors in mice cannot represent an appropriate tumor model to study the development of the bronchogenic carcinomas in humans. The mammary gland adenocarcinomas affecting women cannot be directly related to fibroma and fibroadenomas developing in rats. Similar differences exist regarding the development of an adenocarcinoma of the stomach and the acinar cell carcinoma of the pancreas. The significance of the similarities and the differences in tumor genesis between species will be discussed. Anaplasia is probably not an irreversible alteration since so-called reverse transformation agents may cause neoplastic cells to lose transformation-associated characteristics and assume a morphologic stage approaching that of normal cells. The implications of reverse transformation agents to tumor regression and potential tumor therapy will be discussed.
Human Spontaneous Tumor Profiles J. S. CAMPBELL, Health & M'elfare, Canada, 01-tawa. Ontario, Canada Priority goes to clinical management of human malignancy in the usual community hospital setting, where resources for investigation into environmental, specific occupational, or iatrogenic factors may sometimes be imperfect. Criteria for diagnoses of pseudoneoplastic processes and "borderline" changes are known to be imperfect, and the follow-up studies of controversial cases may be confounded by effects of therapy. Investigation for cause versus spontaniety will not take place if the question as to which is which is not raised in the first place. Comparison from community medicine to the norms of thoroughly studied populations may be confounded by variations in diagnostic interpretation, while exceptional case "clusters" may escape recognition unless cause investigation is meticulous and the results compatible within frames of mass data collection for whole states, countries, or continents. The pathologist can pin down some such soft spots for epidemiologic teams in which he ought to be an active participant, helping lay to rest with the four humors the idea of tumor spontaneity.
Looking at the past to model the future, one finds that very old habits of thought translate into concepts of latent period, of immunologic surveillance, of familial or congenital carcinomaloses. Present models provided by societal fickleness or fatalism. e.g., by way of smoking, lead forcefully away from the idea of spontaneous visitation from the Devil except by way of carcinogenetic conduct. Our lingua franca now swells with oncogenes and oncoviruses, etc., words which have already spilled over into the cocktail circuit. Perhaps there are "spontaneous" human neoplasms, but, ultimately, the elimination or regulation of environmental carcinogens may diminish human cancer out of all recognition.
Man/Animal-induced Tumor Profiles: A Pragmatic Overall View
There is probably more agreement than generally recognized on the limitations and potential value of comparing animal and tumor profiles, whether from a qualitative or quantitative viewpoint. In most species extrapolations, assumptions are made which lack scientific certainty. Such uncertainties stem from the following problems: 1) the difficulties of equating spontaneous and induced neoplastic patterns in one species to the development of cancer in humans or another animal species; 2) the insufficient data in human and animal carcinogenesis to allow qualitative correlations or to determine quantitative dose extrapolations based on generic principles; 3) the deficiencies in comparing lifestyle cancers in humans and rodent models; 4) the relative importance of genotoxic and nongenotoxic carcinogenic agents in animals and humans; and 5) the inadequacy of understanding of pathogenic mechanisms for practical extrapolation in terms of multistage carcinogenesis.
In conclusion, the basic problems remain: 1) the determination of the potential effects in humans of low dose level exposures to potential carcinogenic agents where human data are not available, and 2) the relevance to lifestyle cancers of studies in animals, of modulating factors, made at toxicologic or pharmacologic levels, e.g., hormones or nutrients. It is suggested that conclusions on human relevance are best based on a pragmatic and common sense evaluation of available data, utilizing ad hoc groups of experienced scientists.
Animal Spontaneous Tumor Profiles J. F. HARDISTY, Experimental Pathology Laboratories, Inc., Research Triangle Park, NC Knowledge of the pathology of spontaneous or naturally occurring neoplasms of laboratory animals is essential to their use in carcinogenesis research and testing. Evaluation of experimental results must consider the incidence, type, and behavior of neoplasms in control populations. Evaluation of carcinogenesis experiments for research or safety assessment requires properly designed and well-conducted experiments and knowledge of background data and variations in tumor incidences of control animals. The determination whether a drug is a carcinogen depends upon one or more of the following criteria: 1) increased tumor incidence of a type seen commonly in control animals; 2) a decrease in the latency of tumor appearance in treated animals compared with control animals; 3) appearance of tumor in organs where spontaneous tumors did not occur or of a type of tumor not seen in control animals; and 4) increase in the number of tumors per animal when compared to control animals. Assessment of each of these requires comparisons of results obtained in treated rats to those obtained in concurrent controls. A detailed knowledge of the occurrence of spontaneous tumors is essential.
Many factors can influence the reported incidences of spontaneous tumors leading to variations in tumor incidences of control animals. Many of these factors are widely recognized and study design and pathology protocols minimize their effect on the data from individual studies. These factors include species, strain, sex, age, and source of the experimental test animal. as well as, the study duration, extent of the pathology examination, and dietary conditions. Factors which affect study-to-study variation of the incidence of spontaneous tumors are not as easily identified and therefore are more difficult to control. Possible variables which may affect studyto-study variations in the incidence of spontaneous tumors include laboratory environmental conditions, qualifications and experience of the pathologist, diagnostic criteria, nomenclature conventions, and quality assurance and review procedures.
Data on spontaneous tumors incidence are of value, particularly in the selection of the species of test animal. Of the many species of laboratory animals used in both experimental carcinogenesis and in testing programs, the rat and mouse are most common. A variety of strains and stocks of rats and mice have been used over the years in carcinogenicity studies. Some of the more common strains and stocks of rats used are the inbred F344 (Fischer) and OM (Osborne-Mendel) rat and random bud Sprague-Dawley, Wistar, and to a lesser extent Long Evans and Holtzman stocks. Strains and stocks of mice frequently used include the Swiss and related stocks, the inbred Balb/c strain and (C57Bl/6N X C3H/HeN)F, or B6C3F1 hybrid. There are varyin'g amounts of published data on natural diseases and spontaneous tumor rates for each of these strains and stocks of rats and mice.
Animal-induced Tumor Profiles T. J. Bucci, N.C.T.R., Jefferson, AR Chemical carcinogens induce neoplasms which differ qualitatively and quantitatively from tumors that occur spontaneously in the tissue of interest. While some experimental models have produced neoplasms indistinguishable from their spontaneous counterparts, most cause growths that are histogenically or morphologically different, larger, more numerous, more aggressive, or of shorter latency. Induced tumors may occur in tissues where spontaneous tumors are uncommon.
Cells of induced tumors express phenotypic characteristics (e.g., membrane antigens) not present in corresponding non-neoplastic or spontaneously neoplastic cells. Conversely, some characteristics present in normal or spontaneously neoplastic cells (e.g., certain enzyme activity) may be absent in induced neoplasms.
Not only do carcinogens induce tumors that differ from spontaneous ones, but the effect of a particular Carcinogen varies with the conditions of its use. The species or strain, sex, and age of the host as well as the dose and route of administration are major variables.
Neoplasia is one result of altered cell regulation. If we postulate a central dogma for oncogenesis, induced tumors should arise from the same molecular mechanisms that produce spontaneous tumors. Explanation of the difference in "profile" between induced and spontaneous tu-,nors more probably resides not in differences in oncogenic mechanisms, but rather in the multiplicity of factors which determine the dose of ultimate carcinogen to the sensitive volume of the target cell.
How Does Japan Differentiate Hyperplasia from
Neoplasia? M. ENohfo-ro, Japanese Ministry of Health and Welfare, Tokyo, Japan What a Japanese pathologist could contribute to this fully discussed problem on differentiation of hyperplasia from neoplasia, is to introduce his experience and knowledge in human and experimental pathology of gastric, hepatic, and uterine cervical cancers, all of which are the prevalent cancer diseases in Japan.
Canine and rodent gastric cancers induced experimentally by N-ethyl-N'-nitro-N-nitrosoguanidine or N-methyl-N'-nitro-N-nitrosoguanidine, respectively, show various histologic types, which are very similar to human gastric cancer, examined routinely by endoscopic method. Dog shows the more similar model of human gastric cancer in its morphologic features and responses . to chemotherapy than rat.
Serial liver biopsies performed on patients of liver diseases revealed the final development of liver cell carcinoma in some of them. They all progressed to liver cirrhosis before terminating in carcinoma. However, this does not mean that the hyperplastic nodule is an obligatory precursor of carcinoma in human. Among experimental models of liver cancer produced by large number of agents, only carbon tetrachloride and yellowedrice mycotoxins detected in Japan seem to induce liver cell carcinoma combined with cirrhotic lesions in rodents.
Mode of manifestation of atypical changes in the proliferating cells as a preneoplastic or neoplastic lesions seems to differ according to tissue. Cellular pathology of cervicovaginal smear is reliable for detection of carcinoma at cervix, where the appearance of atypical cells represents a stepping stone between benign and malignant.
Biotransformation and Dose Relationships in Ex-
perimental Oncogenesis D. B. CLAYSON, Health and Welfare Canada, Ottawa, Ontario, Canada The probability of obtaining a tumor in a carcinogenesis bioassay depends mainly on the time on test and on the dose of carcinogen used. There is very limited data on the shape of this surface or reliable data on dose/response or time on test/ response relationships. Ullrich's data on tumor induction by low dose radiation of various types shows a variety of shapes of curve depending on the nature of the radiation involved and the tissue chosen for investigation. As radiation probably does not concern the processes involved in xenobiotic metabolism, these observations clearly demonstrate that factors other than metabolism are important. An attempt will be made to discuss the shape of the dose/response curve in relation to other factors including the background incidence of tumors in a tissue, mechanisms of "nongenotoxic" or toxicity-related carcinogcnesis, and xenobiotic activation of carcinogens. Recently, the National Toxicology Program included a 15-month interim sacrifice in their guidelines for long-term bioassay studies. The principle reasons for this were 2-fold. First, interim sacrifices permit thorough assessment of any toxic effects and aid in defining their pathogenesis. Second, interim sacrifices serve as indicators of potential carcinogenic responses. Furthermore, interim sacrifices can give us an insight into the real incidences of lesions present in a living population at specifie'd ages. It will be demonstrated that neither the incidences of lesions in spontaneously dead animals nor the incidence of the population at risk is reflecting what is going on in a living population at a certain age.
Another aspect that will be discussed is the relation between incidence of lesions and age. In a recent study, in which 2-year and life span data in the F344 rat were compared, we found a clearcut upward trend in incidences for a wide variety of lesions in both sexes after 2 years of age, while an increase in variety of lesions was not observed (Solleveld HA, Hascman JE, and McConnell EE (1984) . The natural history of body weight gain, survival and neoplasia in the Fischer 344 rat. 1.
Natl. Cancer Inst., in press). This means that life span studies do not have an advantage over 2-year studies. In contrast, life span studies have a major disadvantage over 2-year studies, namely a higher background incidence of many types of neoplasms, which increases the inability to separate induced changes from spontaneous background lesions and increases the chance of obtaining statistically false-positive results (Fears TR, Tarone RE, and Chu KC (1977) . False-positive and false-negative rates for carcinogenicity screens. Cancer Aes. 37: 1941 Aes. 37: -1945 . Does that now mean that knowledge of life span is of no value in carcinogenicity testing programs? No, just the opposite is true. The availability of life span data enables us to differentiate compounds that are causing a forward shift in time of neoplasms from those producing enhancement or unique effects, e.g., a much higher incidence of common tumors or development of rare tumors. A distinction which is important for the purpose of risk assessment.
Demonstration of Species, Sex, and Tissue Specificity and Toxicologic-Oncologic Responses C. L. ALDEN, Proctor and Gamble Co., Cincinnati, OH Responsible regulatory decisions regarding the fate of new chemicals require careful evaluation of a host of health, economic, and social factors, in addition to a thorough evaluation of potential risks. In risk assessment, laboratory animals are used as human surrogates in testing for potential chemical effects since mammals are anatomically, physiologically, and biochemically similar and have similar responses to exogenous chemical, biologic, and physical agents (with differences in response usually being quantitative rather than qualitative).
Unfortunately for the sake of proper extrapolation to humans, qualitative differences do occur resulting in species and/or sex and/or tissue specificity in toxicologic/proliferative responses. Since the toxicologic pathologist is trained in comparative medicine, he/she must play a primary role in recongizing and demonstrating specificities in tissue alteration of laboratory animals by new chemicals of potential importance to society. Two models exemplifying the recognition and demonstration of species, sex, and tissue specificity of test substance response will be described. In these models the presumably unique alteration of I ) male rat kidney and 2) rat forestomach occurred, each in response to a specific class of test substances. The decision tree in establishing specificity, as well as the nature of the test substances, will be described.
Review of National Cancer Institute Bioassays G. H. HOTTENDORF, Bristol Laboratories. Syracuse, N Y A total of 251 bioassays have now been reported from the National Cancer Institute/National Toxicology Program carcinogenesis bioassay program; 130 (52%) bioassays were positive, 96 (38%) were equivocal, and 25 (10%) were negative. The distribution of the most recent 59 bioassay results were 32 (54%) positive, 5 (9%) equivocal, and 22 (37%) negative, indicating a shift from equivocal to negative with the positive rate remaining about 50%.
The National Toxicology Program bioassay testing procedures are currently under review. Despite the more reasonable distribution of the most recent results, critical reappraisal of dose selection, the use of the mouse, and the statistical methodology is essential at this time. New perspectives are also still required in the interpretation of bioassay results and their utilization in risk assessment. In addition to genotoxic and epigenetic considerations, pharmacodynamic thresholds can be demonstrated with some therapeutic agents. These agents may represent a third classification of nongenotoxic, nonpromoting, high dose animal "carcinogens."
How Can We Blend Science and the Law into a Meaningful Regulatory Decision?
W. M. COOPER, Williams and Connally, Washington, D.C. Current institutional arrangements for the conduct and assessment of scientific experiments, and the gathering and assessment of data for regulatory purposes are unduly adversarial and consequently do not receive a high degree of public confidence. New institutional arrangements can address this problem by combining. under leadeiship of unquestionable competence and integrity, distinguished scientists and mechanisms of accountability to government and the public. The specifications for such new institutional arrangements are described, and the principal issues raised by the process for their creation are analyzed, by reference to a recently created institution now overseeing studies on the health effects of motor vehicle exhausts.
G. B. GORI, Franklin Institute. Silver Spring, MD In nature, cancer emerges from the multifactorial convergence of many determinants cascading through a network of still unpredictable pathways, dissimilar in various species and even in the same organisms at different times. The ultimate steps causing loss of differentiation might be simple and discrete, but the events leading to them, or those that repair damage once it happens, are probably complex.
In animal testing, the illusion of reproducibility is sometimes achieved by the artful prescription of maximum tolerated doses, usually so high as to overwhelm most natural homeostatic mechanisms. Allegedly, they compensate for the statistical inadequacy of small experimental populations. As it is, different species show vast disparities in genomic potential, activation and deactivation mechanisms, detoxification and repair, and the attending hormonal patterns and feedback dynamics, developmental and aging schedules, evolutionary adaption of diets and environ-I ments, not to mention immunologic and neuroendocrine responses to stress and disease. Such differences have been brushed aside by official pronouncements declaring that adjustments of Sample size or dose shall close the gap that separates man from other species. These propositioiiz are the basis for extensive official testing programs, leading to regulatory decisions of large socioeconomic impact.
Two major factors seems to have fostered the situation. First. unbearable pressure to do something in cancer risk assessment, as the nation is investing over a billion dollars a year for cancer risk. Second, an unwarranted perception of the social responsibility of science. No one could argue that scientific objectives should reflect social issues, but societal or political considerations are out of place in the evaluation of experimental results. Science should not be asked to fabricate images of prudence with no demonstrable scientific relationship to reality. least we compromise its credibility as a discipline and profession.
Except for a handful of agents, today we can define carcinogens only in gross terms, and usually with margins of uncertainty that preclude using this label as a decisive criterion of regulation. More indicative tests can be devised, but they too could give only a generic warning. Because of this uncertainty it is unreasonable to give biosassay results the full veto power they now have in too many regulatory decisions. Such power derives primarily from the Delaney Amendment of the U.S. Food Law, which is interpreted to mean that hazard is a yes or no proposition rather than a continuous range of different risk levels.
The fundamental problem of the Amendment is that it admits no risk and thus no cost-benefit considerations, by allowing only a dichotomous classification of either bad or good substances. In reality, risk-benefit considerations are an integral part of life and, in order to prevent a paralysis of a11 food production, the Delaney Amendment had to be circumvented with the creation of exempt categories, double standards, and artful interpretations of animal tests.
In fact, it is the accumulation of these exceptions and comprises that now besets food regulation, largely because the FDA is increasingly at a loss to justify in plausible ways why certain classifications, exemptions, and allowances should apply to certain substances and not to others.
Therefore, the present regulatory crisis is first a crisis of credibility and only then an obstacle to innovation in food technology. The immediate need is for an open recognition and formalization of the natural exercise of cost-benefit considerations that has continued under many disguises all these years. Until better science is available, society must continue to assume that most sub-stances are risky in some ways, and use them with circumspection. Presently there is no other objective way to care for safety and still pursue the fundamental promise for better lifestyles and health that scientific and technical innovations have so generously provided. Under these terms, use restrictions can be reasonably influenced by bioassay results, but in the end cost-benefit considerations must continue to be overriding determinants of regulation. Such considerations are essential to resolving these issues: they are not crafty political inventions, but the norm of human behavior and the substance of responsible government. In fact, they are inevitable and always held the decisive role in regulatory decisions: we need only to think of the GRAS list, grandfather clauses, aflatoxin, excessive dietary lipids, cigarette smoking, ultraviolet radiation, saccharin. . .
To make reform easier, statutes such as the Delaney Amendment, could remain as moral statements of intent, and be made workable simply by introducing realistic qualifiers. At the same time, the need to seek overall social benefits has intuitive connotations of equity and should have broad voter support. Its statutory prescription should prove a relatively easy task. The methodology of cost-benefit determinations will then become of decisive importance. Congress should establish uniform guidelines for fairness and comparability and avoid spelling out preconceived definitions of tolerable risk. Instead, an open regulatory process will determine in each case which options of use restriction have the greater promise of social gain.
I. C. MUNRO, Canadian Center for Toxicology, Guelph, Ontario, Canada An overview of the regulatory decision-making process will be presented, with special reference to the regulation of chemical carcinogens. Current procedures for assessing human risk on the basis of toxicologic investigations in animal models will be reviewed and a critical appraisal of the available techniques for quantitative risk assessment will be provided. The integration of factors other than risk into the regulatory process, including information on health, economic, and other benefits will be discussed.
Y. NISHIYAMA, Kitasato University, Kanagawa, Preclinical toxicity studies in animals are still the constituent parts of the basis for a drug and a Japan chemical to be accepted by regulatory agencies. However, it also holds true that, as was stated by a WHO Scientific Group 22 years ago ". . . many toxic effects may be predicted from observations made in animals, but, in the present state of knowledge, there are some important toxic effects that are not predictable from animal studies, and this is their main limitation.. . Every effort should be made to build up knowledge of species differences and similarities in toxicological responses." This aspect will also be discussed, based on my own experience of human pathology.
The Japanese Ministry of Health and Welfare, after a considerable length of time, announced the new toxicology testing guidelines which became effective on March 1, 1984 and stipulate details of experimental procedure to be employed for nonclinical animal studies required for registration of new drugs. Thus, the safety evaluation on new drugs should be performed under new mode circumstances. However, toxicologic studies alone cannot give the desired information and decision, but should be considered deeply together with pharmacokinetics, pharmacodynamics, risk-benefit ratio, and structure-activity relationship of the new chemical entity. It is felt that much more correlation of data related with findings of small animal studies and human toxicities are desirable in near future. J. A. TODHUNTER, Todhunter Associates, Silver Spring, MD It seems apparent that while laivyers and scientists view the world from radically different perspectives, there are ways in which the relative merits of each system can complement each other. Certainly, if we are to have a system of regulation and of safety management which both works effectively and is rational, ive need to bridge the chasm which divides the two communities. As discussed, a good first step might be for the legal community to understand that science is constantly changing and evolving. The concept of res judicata is inappropriate in dealing with scientific issues. On the same note, the scientific community needs to become much more actively involved in communicating with the legal community. In doing so, scientists need to understand that the legal community exists in large part as a societal mechanism for conflict resolution and as such, needs to know not only what is possible, but what is plausible and probable.
